Daniel Teper

Daniel Teper

Company: Cytovia Therapeutics

Job title: CEO


Development of Gene Edited iPSC CAR-NK Cell Therapy & Opportunities for Rational Design 3:10 pm

Clinical promise of CAR NK cell therapy: advantages over CAR-Ts and other T-Cell therapies CAR NKs and multi-specific NK engagers: competitors or complementary approaches to harness the power of NK cells Allogeneic CAR NK cells: are IPSCs the new best standard? Gene editing and rational design of CAR NKs Targeting solid tumors with CAR NKsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.